Remove Drug Research Remove Immune Response Remove Research
article thumbnail

In vivo preclinical models for immune-mediated inflammatory disease drug development

Crown Bioscience

In this blog we will explore immune-mediated inflammatory diseases (IMIDs) —which represent a diverse group of conditions characterized by an excessive and/or inappropriate immune response.

Disease 52
article thumbnail

AI in gene delivery vector discovery and design

Drug Target Review

Alipogene tiparvovec and voretigene neparvovec-rzyl, two recombinant AAV-based gene therapy products, were approved by the European Medicines Agency (EMA) to treat lipoprotein lipase deficiency in 2012 2 and by the US Food and Drug Administration (FDA) to treat inherited retinal dystrophy in 2017, respectively.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery

DrugBank

The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess. Researchers would sift through natural extracts , hoping to stumble upon a compound that exhibited beneficial effects. In fact, it's one of the most exciting areas in drug research today.

article thumbnail

ACTIV Update: Making Major Strides in COVID-19 Therapeutic Development

NIH Director's Blog: Drug Development

These include drugs that you may have heard about on the news: remdesivir (an antiviral), dexamethasone (a steroid), and monoclonal antibodies from the companies Eli Lilly and Regeneron. Therapeutics Clinical Working Group : Prioritizes therapeutic agents for testing within an adaptive master protocol strategy for clinical research.